Navigation Links
Evidence links anemia drugs with leukemic transformation in patients with primary myelofibrosis
Date:12/10/2007

ATLANTA -- Mayo Clinic researchers today reported the discovery of a link between erythropoiesis-stimulating agents (ESAs) and leukemic transformation (conversion to leukemia) of the blood disorder myelofibrosis. The results of the retrospective study, which sought to quantify the risk factors for leukemic transformation, were presented by lead author Jocelin Huang, M.D., at the American Society of Hematologys annual meeting.

We believe this to be the first large systematic evaluation of the risk factors leading to leukemic transformation in primary myelofibrosis, says Dr. Huang, hematology researcher at Mayo Clinic. And in the process, we discovered some unexpected results.

The researchers confirmed a number of clinical and laboratory variables that appeared to correlate with leukemic transformation. Independent risk factors for development of leukemia included peripheral blood blast (immature leukemia cells) levels greater than or equal to 3 percent; and a platelet count of less than 100x109/liter (L). The more surprising findings were that specific treatments also appeared to be related to leukemic transformation. Use of ESAs or danazol (a hormone with anemia-countering properties) were linked to later development of leukemia, independent of the blast or platelet levels.

Ayalew Tefferi, M.D., principal investigator of the study, and a Mayo Clinic hematologist, cautions that the current findings are based on retrospective observation and need to be validated in properly designed prospective studies. While we cannot take these findings as an absolute, at the same time, they cannot be ignored, says Dr. Tefferi. Treatment decisions regarding the use of ESAs in patients with primary myelofibrosis should carefully be evaluated.

He also points out that ESA treatment in patients with primary myelofibrosis has the potential to cause further enlargement of the spleen (a known complication of the disease).

The study evaluated the records of 311 Mayo Clinic patients, seen with primary myelofibrosis between 1976 and 2006. Of these patients, at an average follow-up of 27 months, 27 cases (9 percent) of leukemic transformation were documented.

Other factors appeared to contribute to the development of leukemia, including anemia, leukocytosis and peripheral blood monocyte count greater than or equal to 1x109/L (both are measures of elevated white blood cells), hypercatabolic symptoms (results of excess metabolism), a splenectomy and treatment with androgens (a type of hormones). However, they were not independent predictors.


'/>"/>

Contact: Elizabeth Zimmermann
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Jefferson researchers uncover new evidence of prolactins possible role in breast cancer
2. No strong evidence linking amateur boxing with long-term brain injury
3. AHRQ Announces Next Phase of Its Evidence-Based Practice Center Program
4. Vanderbilt Medical Center chosen as Evidence-based Practice Center
5. Little Evidence Silicone Breast Implants Harm Health
6. Consumers Should Demand Evidence, Not Guesswork, On Meat-Cancer Links
7. U of M study: Medicare lacks tools, incentives to enforce evidence-based coverage policies
8. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
9. Scientific evidence of the significant anti-cancer effect of milk thistle
10. Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace
11. UC Davis researchers find evidence of mature heart cell potential in embryonic stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... thrilled to formally announce its Not a Moment to Lose fundraising campaign. As ... rally supporters dedicated to declaring victory over cancer. The campaign aims to raise ...
(Date:12/6/2016)... ... 2016 , ... GrekTek LLC, ( http://www.grektek.com ) an mHealth ... ) for the HealthyWatch, a new device to help patients manage their health ... while sharing these events with caregivers in real time. , “One ...
(Date:12/6/2016)... Canada (PRWEB) , ... December 06, 2016 , ... ... announce the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS ... IAPC EHS audit protocols to understand the scope of their EHS regulatory obligations ...
(Date:12/5/2016)... ... December 05, 2016 , ... What: Shriners Hospitals for Children, ... Pole to our patients – using a video monitor and web-enabled camera. Santa visits ... transform the Auditorium into a Christmas Wonderland, which is where the video connection to ...
(Date:12/5/2016)... ... December 05, 2016 , ... SyncDog, Inc., ... in SuperbCrew magazine, a leading online tech news platform connecting technology innovators with ... on SuperbCrew.com, explores the state of enterprise mobility security today, and how the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016   TrainerMD , the first ... announced a new collaboration with Styku . Styku, ... leverages Microsoft Kinect hardware to provide users world-class, real-time 3D body ... now have the means to see, hear and feel their health ... , ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
(Date:12/5/2016)... -- For the third consecutive year, Astellas has achieved ... Campaign Foundation,s (HRC) annual Corporate Equality Index ... used to rate companies on policies and practices concerning ... For the last 15 years, HRC has released ... efforts, culture and business practices. The survey rates business ...
Breaking Medicine Technology: